Experimental Drug Elraglusib Doubles One-Year Survival in Pancreatic Cancer Patients
A new study has reported that an experimental drug, elraglusib, has doubled the one-year survival rates for patients with pancreatic cancer, a disease known for its poor prognosis. The drug works by targeting the protective web that pancreatic tumors create around themselves, allowing immune molecules and chemotherapy to penetrate more effectively. The study, published in Nature Medicine, involved 286 patients with advanced pancreatic cancer. Those treated with elraglusib and chemotherapy had a median survival of 10.1 months, compared to 7.2 months for those receiving only chemotherapy. The study highlights a significant advancement in pancreatic cancer treatment, which has seen little progress over the past two decades. 
